Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference
July 09 2020 - 4:01PM
Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company
focused on Alzheimer’s disease, today announced that its lead
neuroscientist, Lindsay H. Burns, PhD, will give a keynote
presentation at the Biomarkers for Alzheimer’s Disease Summit, a
virtual conference, on July 15, 2020. Dr. Burns’ talk will focus on
SavaDx, the Company’s investigational diagnostic to detect
Alzheimer’s disease with a simple blood test.
The Biomarkers for Alzheimer’s Disease Summit is
a scientific forum dedicated to solving the challenges of
developing clinically validated biomarkers to detect Alzheimer’s
disease.
Dr. Burns, SVP, Neuroscience at Cassava
Sciences, co-discovered PTI-125, the Company’s novel, proprietary
drug candidate to treat Alzheimer’s disease and other disorders.
She has led the Company’s program in Alzheimer’s disease through
basic research, target identification and validation, medicinal
chemistry, lead discovery & profiling, pharmacology,
mechanism-of-action studies and clinical biomarker assessments. Dr.
Burns was trained in neuroscience at the University of Cambridge
and Harvard College.
Cassava Sciences’ scientific presentation for
this conference can be accessed July 15, 2020 on the ‘Investors’
page of the Company’s website: https://www.CassavaSciences.com
About SavaDxSavaDx (formerly,
PTI-125Dx) is Cassava Sciences’ investigational diagnostic to
detect Alzheimer’s disease. The goal of SavaDx is to make the
detection of Alzheimer’s as simple as getting a blood test,
possibly years before the appearance of any overt clinical
symptoms. This clinical-stage program is substantially funded by a
research grant award from the National Institutes of Health
(NIH).
About PTI-125Cassava Sciences’
lead therapeutic product candidate is for the treatment of
Alzheimer’s disease. PTI-125 is a proprietary, small molecule
(oral) drug that restores the normal shape and function of altered
filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA
in the brain disrupts the normal function of neurons, leading to
Alzheimer’s pathology, neurodegeneration and neuroinflammation. The
underlying science is published in peer-reviewed scientific
journals, including Journal of Neuroscience, Neurobiology of Aging,
Journal of Biological Chemistry and Journal of Prevention of
Alzheimer’s Disease.
In the first half of 2020, Cassava Sciences
completed a randomized, placebo-controlled Phase 2b study of
PTI-125 in patients with Alzheimer’s disease. A full assessment of
drug effects on cognition and biomarkers of disease is on-going.
Cassava Sciences expects to announce results of these clinical
analyses approximately Q3 2020.
About Alzheimer's
Disease Alzheimer’s disease is a progressive brain
disorder that destroys memory and thinking skills. Currently, there
are no drug therapies to halt Alzheimer’s disease, much less
reverse its course. In the U.S. alone, approximately 5.8 million
people are currently living with Alzheimer’s disease, and
approximately 487,000 people age 65 or older developed Alzheimer’s
in 2019.1 The number of people living with Alzheimer’s disease is
expected to grow dramatically in the years ahead, resulting in a
growing social and economic burden.2
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover & develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. Cassava Sciences owns worldwide
development and commercial rights to its research programs in
Alzheimer’s disease, and related technologies, without royalty
obligations to any third-party.
For more information, please visit:
https://www.CassavaSciences.com
For Media Inquiries
Contact:Kirsten Thomas, SVP The Ruth
Groupkthomas@TheRuthGroup.com (508) 280-6592
Cautionary Note Regarding
Forward-Looking Statements: This press release contains
“forward-looking statements” for purposes of the Private Securities
Litigation Reform Act of 1995 (the Act). Cassava Sciences claims
the protection of the Safe Harbor for forward-looking statements
contained in the Act. All statements other than statements of
historical fact contained in this press release, including, but not
limited to, statements regarding the status of clinical studies
with PTI-125; the timing of announcing clinical results of our
Phase 2b study of PTI-125, including biomarker and cognition data;
the interpretation of results of our Phase 2 clinical studies;
potential health benefits, if any, of changes in levels of
biomarkers; variability in levels of biomarkers of disease; verbal
commentaries made by Cassava Sciences’ employees; and potential
benefits, if any, of the Company’s product candidates for
Alzheimer’s disease, are forward-looking statements. Such
statements are based largely on the Company’s current expectations
and projections about future events. Such statements speak only as
of the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including, but not limited
to, those risks relating to the ability to conduct or complete
clinical studies on expected timelines, to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates, the severity and duration of health care
precautions given the COVID-19 pandemic, any unanticipated impacts
of the pandemic on our business operations, and including those
described in the section entitled “Risk Factors” in Cassava
Sciences’ Annual Report on Form 10-K for the year ended December
31, 2019 and future reports to be filed with the SEC. In light of
these risks, uncertainties and assumptions, the forward-looking
statements and events discussed in this press release are
inherently uncertain and may not occur, and actual results could
differ materially and adversely from those anticipated or implied
in the forward-looking statements. Accordingly, you should not rely
upon forward-looking statements as predictions of future events.
Except as required by law, the Company disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release. For further information
regarding these and other risks related to our business, investors
should consult our filings with the SEC, which are available on the
SEC's website at www.sec.gov.
1, 2 Source: Alzheimer’s Association. 2019 Alzheimer’s Disease
Facts and Figures. Available online at:
https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Sep 2023 to Sep 2024